Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,234 total articles
Green Dot (GDOT) looks attractively mispriced after a run of negative headlines. With free cash flow of $97.2M, a market cap of ~$623M and price-to-free-cash-flow near 6.5, the risk/reward favors a tactical long. This trade idea lays out an entry at $11.22, a stop at $9.80 and a primary target of $14.50 over a 45-trading-day horizon, with clear cat…
IAMGOLD (IAG) is trading like a distressed miner despite record production in 2025, clear 2026 guidance and a balance sheet that can tolerate growth. With current price action and an implied valuation that looks inexpensive under realistic gold-price scenarios, a position-sized long makes sense for disciplined traders.
AEM has been hit hard alongside the recent gold rout, but the company’s scale, diversified assets and dividend policy create a tactical risk-reward for a mid-term swing trade. Technicals show oversold momentum and price sitting below key moving averages; fundamentals — including a near-$100B market cap and modest yield — support a disciplined long …
Evotec's American Depositary Shares recently traded near the 52-week low after a restructuring announcement and attendant legal noise. The business still owns a differentiated discovery and biologics services franchise, the valuation sits under $900M, and technicals show oversold conditions. This trade idea targets a bounce into the $3.40 area over…
AirSculpt Technologies (AIRS) trades at a modest market cap and single-digit revenue multiple despite recent declines in case volume. The company has trimmed debt, generated positive free cash flow, and shows technical signs of a base. At $2.78 the risk/reward looks attractive for a tactical long; size positions appropriately and respect a tight st…
Lufax (LU) is trading at $2.29 with a market cap of $2.43B, a PB of 0.18 and heavy headline risk from an accounting scandal. That dislocation creates an asymmetric opportunity: sell a cash-secured $2.00 put (mid-term, ~45 trading days) for an assumed $0.87 premium to realize a 38% yield on capital at risk. The thesis rests on a large reported cushi…
CrowdStrike’s expanding AI-driven Managed Detection and Response (MDR) capabilities, underpinned by a deeper collaboration with NVIDIA and integrations with enterprise AI tooling, are a plausible catalyst to accelerate revenue per customer and improve retention. The stock still trades at a premium (P/S ~22.8) that reflects growth expectations; this…
National Energy Services Reunited (NESR) has more than doubled from its 52-week low and recently rallied on new cementing contracts, yet the company still trades at a market cap roughly in line with 1.6x trailing revenue and technicals show room to run if execution on new wins proceeds. This trade idea lays out a precise entry at $20.35, stop loss …
VNET Group provides a play on accelerating AI and cloud demand in China while trading well below recent peak levels. The shares look constructive near $9.70 with a clear stop and upside toward prior highs if revenue and margin trends stabilize.
Energy Transfer (ET) offers a 7%+ distribution yield, solid distributable cash flow coverage, and a string of near-term catalysts — from SPR flows to AI-driven gas demand — that justify a tactical long position. Balance sheet leverage and macro risk require a disciplined entry and stop.
Markel (MKL) combines durable insurance underwriting, a growing Markel Ventures platform and a large investment float. At roughly $24.3B market cap and trading near $1,930, the stock sits at ~12x earnings, ~1.33x book and EV/EBITDA of ~7.8 — valuation levels that read like an opportunity for long-term investors. This trade idea lays out a disciplin…
Palantir shares trade with stretched multiples, but recent results and a new Nvidia partnership make a case for upside as enterprise adoption of agentic AI moves from pilots to operations. This trade idea lays out an entry at $154.35, a stop at $140.00 and staged targets at $180.00 and $207.52, with a clear horizon and risk plan.
Coinbase's Q1 guidance and recent regulatory tailwinds removed a major overhang. With a $53B market cap, improving technicals, and strong liquidity metrics, this is a tactical long trade sized to a mid-term horizon. Entry $195, stop $170, target $260 - horizon 45 trading days.
Smurfit Westrock aims to become the largest pure-play packaging integrator by combining complementary assets, cost bases, and geographic reach. The trade idea is a tactical long position that bets on successful integration and margin expansion over the next 180 trading days, with defined entry, stop and target levels and a clear risk framework.
Bilibili shows durable DAU-led monetization and an ad rebound that is already lifting margins. With a market cap near $11.0B, improving operating profit and a recent string of positive quarters justify a tactical long in the mid term (45 trading days). Trade plan, catalysts and risks laid out below.
Emeren Group Ltd (SOL) is a small-cap renewable developer trading near multi-month technical support. The company generates the majority of its revenue from electricity generation and operates across China and key European markets. With a market cap under $100M, constructive moving averages, and a manageable short-interest profile, SOL offers a hig…
MP Materials (MP) is the dominant U.S. rare-earth producer with a newly integrated processing-to-magnetics footprint. With market cap around $10.45B, EV roughly $10.37B, and tangible government and commercial contracts supporting higher realized prices, MP looks set to capture margin expansion as the industry faces a structural heavy-rare-earth def…
Fuel costs move markets in the near term, but Boeing's revenue mix, backlog, defense exposure and aftermarket services make it a decade play. Here is an actionable long trade with entry, stop and target aimed at capturing multi-quarter normalization and margin recovery while containing downside from cyclical shocks.
SentinelOne reported milestone results and guidance that disappointed some traders, but fundamentals and technicals argue for a disciplined long. A mid-term swing trade with a clear stop and a $19 target balances upside from re-rating and partnerships against execution and macro risks.
Apple's combination of premium hardware, tight software integration, and a massive services annuity positions it to monetize the next wave of AI without abandoning the company's design-first playbook. Valuation is elevated but supported by $123.3B free cash flow and an EPS of $8.02. We upgrade to a constructive rating and lay out an actionable trad…
Pfizer ($PFE) looks well positioned for a mid-term rebound. The stock is trading near $27 with a market cap around $156B, strong free cash flow (~$10.4B) and a chunky dividend yield (~6.2%). Recent positive oncology data and a new approval reduce headline risk, while technicals and heavy short interest create conditions for an outsized bounce. This…
Celestica is increasingly exposed to the AI data-center build cycle via a new AMD partnership and has the balance sheet and cash flow to scale production. The shares trade at premium multiples, but the combination of high ROE, accelerating enterprise wins and clean leverage makes a calculated long trade attractive for traders willing to hold throug…
AMD is beginning to realize the benefits of scale across its data-center CPU and GPU franchises. This trade targets a material move higher as EPYC and data-center GPU adoption combine with improving cost leverage. Entry, stop and target reflect a 6- to 9-month view while keeping room for near-term macro volatility.
DocuSign appears to be turning a corner: subscription stability, nearly $1B in free cash flow, and a sub-$10B enterprise value give investors a priced-in bear case. This trade idea lays out a concrete long entry, stop, and target with a 180-trading-day horizon, balancing upside from product-led AI adoption against execution and sector risks.
GSK is executing a clear playbook: grow vaccines and specialty franchises, accelerate oncology and HIV investments via pipeline and selective buys, and defend margins with commercial scale. The stock trades at a reasonable multiple for a major pharma and yields ~3.3%. We like a long exposure with disciplined risk management, targeting a move back t…
